A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia

Sumithira Vasu; Jessica K. Altman; Geoffrey L. Uy; Martin S. Tallman; Ivana Gojo; Gerard Lozanski; Ute Burkard; Annika Osswald; Pamela James; Björn Rüter; William Blum

doi:10.3324/haematol.2020.274118

A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia

Sumithira Vasu, Jessica K. Altman, Geoffrey L. Uy, Martin S. Tallman, Ivana Gojo, Gerard Lozanski, Ute Burkard, Annika Osswald, Pamela James, Björn Rüter, William Blum

Research output: Contribution to journal › Letter › peer-review

10 Scopus citations

Original language	English
Pages (from-to)	770-773
Number of pages	4
Journal	Haematologica
Volume	107
Issue number	3
DOIs	https://doi.org/10.3324/haematol.2020.274118
State	Published - Mar 2022

Access to Document

10.3324/haematol.2020.274118

Cite this

Vasu, S., Altman, J. K., Uy, G. L., Tallman, M. S., Gojo, I., Lozanski, G., Burkard, U., Osswald, A., James, P., Rüter, B., & Blum, W. (2022). A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia. Haematologica, 107(3), 770-773. https://doi.org/10.3324/haematol.2020.274118

@article{78b8f1a7445b4ca78e781624035eee0f,

title = "A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia",

author = "Sumithira Vasu and Altman, {Jessica K.} and Uy, {Geoffrey L.} and Tallman, {Martin S.} and Ivana Gojo and Gerard Lozanski and Ute Burkard and Annika Osswald and Pamela James and Bj{\"o}rn R{\"u}ter and William Blum",

note = "Funding Information: Acknowledgements: the authors would like to thank the patients and their families, the research staff and Anne Esler for statistical analysis. Medical writing assistance during the preparation of this manuscript was provided by Lynn Pritchard, Ashfield MedComms, an Ashfield Health Company, which was funded by Boehringer Ingelheim. Funding: this work was supported by Boehringer Ingelheim. Funding Information: Disclosures: SV reports receiving funding from Boehringer Ingelheim for Advisory Board participation. JKA reports being part of an advisory council or committee for Astellas, Novartis, Cancer Expert Now, Agios, Glycomimetics, Theradex, AbbVie and Daiichi Sankyo, and being a speaker for PeerView, prIME Oncology, France Foundation. GLU reports receiving honoraria from Astellas and consulting fees from Genentech and Jazz. MST reports being part of an advisory council or committee for AbbVie, Daiichi-Sankyo, Orsenix, KAHR, Rigel, Delta Fly Pharma, Tetraphase, Oncolyze, Jazz Pharma, Roche, Biosight and Novartis, receiving grants or funds from AbbVie, Orsenix, ADC Therapeutics, Biosight, Glycomimetics, Rafael and Amgen, and other potential financial relationship with UpToDate. IG reports receiving grants or funds from Merck, Amgen, Amphivena, Celgene and Genentech. GL reports receiving funding of flow cytometry analysis of samples for this study from Boehringer Ingelheim. UB and AO report employment with Boehringer Ingelheim Pharma GmbH & Co. KG. PJ reports no conflict of interests. BR reports employment and other potential financial relationship with Boehringer Ingelheim Pharmaceuticals Inc. WB reports receiving consulting fees from Amerisource Bergen and grants or funds from Leukemia and Lymphoma Society, Xencor, Forma, Celyad and Novartis.",

year = "2022",

month = mar,

doi = "10.3324/haematol.2020.274118",

language = "English",

volume = "107",

pages = "770--773",

journal = "Haematologica",

issn = "0390-6078",

number = "3",

}

Vasu, S, Altman, JK, Uy, GL, Tallman, MS, Gojo, I, Lozanski, G, Burkard, U, Osswald, A, James, P, Rüter, B & Blum, W 2022, 'A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia', Haematologica, vol. 107, no. 3, pp. 770-773. https://doi.org/10.3324/haematol.2020.274118

TY - JOUR

T1 - A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia

AU - Vasu, Sumithira

AU - Altman, Jessica K.

AU - Uy, Geoffrey L.

AU - Tallman, Martin S.

AU - Gojo, Ivana

AU - Lozanski, Gerard

AU - Burkard, Ute

AU - Osswald, Annika

AU - James, Pamela

AU - Rüter, Björn

AU - Blum, William

N1 - Funding Information: Acknowledgements: the authors would like to thank the patients and their families, the research staff and Anne Esler for statistical analysis. Medical writing assistance during the preparation of this manuscript was provided by Lynn Pritchard, Ashfield MedComms, an Ashfield Health Company, which was funded by Boehringer Ingelheim. Funding: this work was supported by Boehringer Ingelheim. Funding Information: Disclosures: SV reports receiving funding from Boehringer Ingelheim for Advisory Board participation. JKA reports being part of an advisory council or committee for Astellas, Novartis, Cancer Expert Now, Agios, Glycomimetics, Theradex, AbbVie and Daiichi Sankyo, and being a speaker for PeerView, prIME Oncology, France Foundation. GLU reports receiving honoraria from Astellas and consulting fees from Genentech and Jazz. MST reports being part of an advisory council or committee for AbbVie, Daiichi-Sankyo, Orsenix, KAHR, Rigel, Delta Fly Pharma, Tetraphase, Oncolyze, Jazz Pharma, Roche, Biosight and Novartis, receiving grants or funds from AbbVie, Orsenix, ADC Therapeutics, Biosight, Glycomimetics, Rafael and Amgen, and other potential financial relationship with UpToDate. IG reports receiving grants or funds from Merck, Amgen, Amphivena, Celgene and Genentech. GL reports receiving funding of flow cytometry analysis of samples for this study from Boehringer Ingelheim. UB and AO report employment with Boehringer Ingelheim Pharma GmbH & Co. KG. PJ reports no conflict of interests. BR reports employment and other potential financial relationship with Boehringer Ingelheim Pharmaceuticals Inc. WB reports receiving consulting fees from Amerisource Bergen and grants or funds from Leukemia and Lymphoma Society, Xencor, Forma, Celyad and Novartis.

PY - 2022/3

Y1 - 2022/3

UR - http://www.scopus.com/inward/record.url?scp=85125554545&partnerID=8YFLogxK

U2 - 10.3324/haematol.2020.274118

DO - 10.3324/haematol.2020.274118

M3 - Letter

C2 - 34854276

AN - SCOPUS:85125554545

SN - 0390-6078

VL - 107

SP - 770

EP - 773

JO - Haematologica

JF - Haematologica

IS - 3

ER -

A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia

Access to Document

Other files and links

Cite this